1. Home
  2. VRAX vs CHEK Comparison

VRAX vs CHEK Comparison

Compare VRAX & CHEK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VRAX
  • CHEK
  • Stock Information
  • Founded
  • VRAX 2013
  • CHEK 2004
  • Country
  • VRAX United Kingdom
  • CHEK Israel
  • Employees
  • VRAX N/A
  • CHEK N/A
  • Industry
  • VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • CHEK Medical Electronics
  • Sector
  • VRAX Health Care
  • CHEK Health Care
  • Exchange
  • VRAX Nasdaq
  • CHEK Nasdaq
  • Market Cap
  • VRAX 7.3M
  • CHEK 9.0M
  • IPO Year
  • VRAX 2022
  • CHEK 2015
  • Fundamental
  • Price
  • VRAX $2.04
  • CHEK $0.86
  • Analyst Decision
  • VRAX
  • CHEK
  • Analyst Count
  • VRAX 0
  • CHEK 0
  • Target Price
  • VRAX N/A
  • CHEK N/A
  • AVG Volume (30 Days)
  • VRAX 291.7K
  • CHEK 74.4K
  • Earning Date
  • VRAX 02-05-2025
  • CHEK 02-25-2025
  • Dividend Yield
  • VRAX N/A
  • CHEK N/A
  • EPS Growth
  • VRAX N/A
  • CHEK N/A
  • EPS
  • VRAX N/A
  • CHEK N/A
  • Revenue
  • VRAX $84,872.00
  • CHEK N/A
  • Revenue This Year
  • VRAX $5,169.18
  • CHEK N/A
  • Revenue Next Year
  • VRAX $66.97
  • CHEK N/A
  • P/E Ratio
  • VRAX N/A
  • CHEK N/A
  • Revenue Growth
  • VRAX 7.03
  • CHEK N/A
  • 52 Week Low
  • VRAX $0.60
  • CHEK $0.56
  • 52 Week High
  • VRAX $9.00
  • CHEK $3.45
  • Technical
  • Relative Strength Index (RSI)
  • VRAX 53.40
  • CHEK 41.46
  • Support Level
  • VRAX $1.58
  • CHEK $0.81
  • Resistance Level
  • VRAX $2.29
  • CHEK $0.97
  • Average True Range (ATR)
  • VRAX 0.24
  • CHEK 0.10
  • MACD
  • VRAX 0.00
  • CHEK -0.03
  • Stochastic Oscillator
  • VRAX 66.22
  • CHEK 10.44

About VRAX Virax Biolabs Group Limited

Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.

About CHEK Check-Cap Ltd.

Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.

Share on Social Networks: